admin Cell therapies require precise screening and monitoring of patients to ensure that the transfer of either autologous or allogeneic cells to a patient results in a therapeutic effect to targeted organs or tissues.
MILPITAS, Calif.–(BUSINESS WIRE)–ASC Therapeutics, a privately held biopharmaceutical company pioneering the development of transformative in-vivo …
UMass Medical School researchers Guangping Gao, PhD, and Dan Wang, PhD, are working with ASC Therapeutics, a privately held biopharmaceutical company developing in-vivo gene replacement, gene editing and allogeneic cell therapies, to bring a gene therapy for maple syrup urine disease (MSUD) to the clinic. “Our significant progress developing an AAV-based therapy for MSUD will … Read more
MILPITAS, Calif.–(BUSINESS WIRE)–ASC Therapeutics, a privately-held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies, today announced a partnership with the University of Massachusetts Medical School (UMMS) to co-develop a gene therapy for Maple Syrup Urine Disease (MSUD). “We look forward to working with the UMMS team led … Read more
The U.S. Food and Drug Administration (FDA) has approved ASC Therapeutics’ request to open a clinical trial in the U.S. into the safety and early efficacy of ASC618, its second-generation gene therapy for hemophilia A. A Phase 1/2 trial (NCT04676048), set to start this month, will test the one-time therapy in up to 12 adults with moderate … Read more
BusinessWire Transformational in-vivo AAV gene therapy for hemophilia A Efficiently biosynthesized and secreted bioengineered factor VIII Potentially leads to lower vector dose, reduced cost and extended durability MILPITAS, Calif.–ASC Therapeutics, a privately-held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies for hematologic and other rare disorders today … Read more
ASC Therapeutics “Advanced Genome Editing, Gene & Cell Therapy Platforms in the US and China” won the first prize of the “2021 Fifth Forum For New Drug R&D And Bio-Pharma Projects Roadshow” held on June 24, 2021 in Nanjing Biomedical Valley. Our CEO Ruhong Jiang, PhD, described our three platforms for second-generation gene therapy, CRISPR … Read more
